title: Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
abstract: OBJECTIVE
  To compare the prognostic ability of inflammation scores for patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).
  
  
  METHODS
  Data of 224 consecutive patients who underwent TACE for unresectable HBV-related HCC from September 2009 to November 2011 were retrieved from a prospective database. The association of inflammation scores with clinicopathologic variables and overall survival (OS) were analyzed, and receiver operating characteristic curves were generated, and the area under the curve (AUC) was calculated to evaluate the discriminatory ability of each inflammation score and staging system, including tumor-node-metastasis, Barcelona Clinic Liver Cancer, and Cancer of the Liver Italian Program (CLIP) scores.
  
  
  RESULTS
  The median follow-up period was 390 d, the one-, two-, and three-year OS were 38.4%, 18.3%, and 11.1%, respectively, and the median OS was 390 d. The Glasgow Prognostic Score (GPS), modifed GPS, neutrophil-lymphocyte ratio, and Prognostic Index were associated with OS. The GPS consistently had a higher AUC value at 6 mo (0.702), 12 mo (0.676), and 24 mo (0.687) in comparison with other inflammation scores. CLIP consistently had a higher AUC value at 6 mo (0.656), 12 mo (0.711), and 24 mo (0.721) in comparison with tumor-node-metastasis and Barcelona Clinic Liver Cancer staging systems. Multivariate analysis revealed that alanine aminotransferase, GPS, and CLIP were independent prognostic factors for OS. The combination of GPS and CLIP (AUC = 0.777) was superior to CLIP or GPS alone in prognostic ability for OS.
  
  
  CONCLUSIONS
  The prognostic ability of GPS is superior to other inflammation scores for HCC patients undergoing TACE. Combining GPS and CLIP improved the prognostic power for OS.
authors.affiliation: Dong-Sheng Zhou, Li Xu, Feng-Ying He, Jun-Ting Huang, Yao-Jun Zhang, Min-Shan Chen, Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Dong-Sheng
authors.initials: DS
authors.lastname: Zhou
authors.affiliation: Dong-Sheng Zhou, Li Xu, Feng-Ying He, Jun-Ting Huang, Yao-Jun Zhang, Min-Shan Chen, Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Li
authors.initials: L
authors.lastname: Xu
authors.affiliation: Dong-Sheng Zhou, Li Xu, Feng-Ying He, Jun-Ting Huang, Yao-Jun Zhang, Min-Shan Chen, Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Yao-Ling
authors.initials: YL
authors.lastname: Luo
authors.affiliation: Dong-Sheng Zhou, Li Xu, Feng-Ying He, Jun-Ting Huang, Yao-Jun Zhang, Min-Shan Chen, Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Feng-Ying
authors.initials: FY
authors.lastname: He
authors.affiliation: Dong-Sheng Zhou, Li Xu, Feng-Ying He, Jun-Ting Huang, Yao-Jun Zhang, Min-Shan Chen, Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Jun-Ting
authors.initials: JT
authors.lastname: Huang
authors.affiliation: Dong-Sheng Zhou, Li Xu, Feng-Ying He, Jun-Ting Huang, Yao-Jun Zhang, Min-Shan Chen, Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Yao-Jun
authors.initials: YJ
authors.lastname: Zhang
authors.affiliation: Dong-Sheng Zhou, Li Xu, Feng-Ying He, Jun-Ting Huang, Yao-Jun Zhang, Min-Shan Chen, Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
authors.forename: Min-Shan
authors.initials: MS
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy* / Q000821:virology; D016461:Chemoembolization, Therapeutic; D016009:Chi-Square Distribution; D016208:Databases, Factual; D003661:Decision Support Techniques; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000175:diagnosis* / Q000401:mortality; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy* / Q000821:virology; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009504:Neutrophils; D010976:Platelet Count; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012372:ROC Curve; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis; D000075462:Serum Albumin, Human; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C422455:ALB protein, human; D015415:Biomarkers; D018836:Inflammation Mediators; D012709:Serum Albumin; D002097:C-Reactive Protein; D000075462:Serum Albumin, Human
keywords: Hepatocellular carcinoma; Inflammation-based prognostic score; Prognostic index; Staging system; Transarterial chemoembolization